- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.02. | Creative Medical receives WHO designation for second cell therapy | 3 | Investing.com | ||
| 10.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline | 2 | GlobeNewswire (USA) | ||
| 13.01. | Creative Medical reports positive interim data for back pain therapy | 3 | Investing.com | ||
| 13.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | 299 | GlobeNewswire (Europe) | PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 06.01. | Creative Medical erhält behördliche Genehmigung für BioDefense-Initiative | 2 | Investing.com Deutsch | ||
| CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 06.01. | Creative Medical's BioDefense initiative receives regulatory approval | 1 | Investing.com | ||
| 06.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative | 172 | GlobeNewswire (Europe) | PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 31.12.25 | Aktionäre von Creative Medical Technology genehmigen Ausübung von Optionsscheinen | 1 | Investing.com Deutsch | ||
| 31.12.25 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.25 | Creative Medical Wraps Up ADAPT Trial Enrollment For Chronic Lower Back Pain | - | RTTNews | ||
| 17.12.25 | Creative Medical completes enrollment in chronic back pain trial | 2 | Investing.com | ||
| 17.12.25 | Meilenstein für Creative Medical: Patientenrekrutierung für Studie zu chronischen Rückenschmerzen abgeschlossen | 1 | Investing.com Deutsch | ||
| 17.12.25 | Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point | 189 | GlobeNewswire (Europe) | PHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced... ► Artikel lesen | |
| 02.12.25 | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201 | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Creative Medical Technology Holdings genehmigt Boni für CEO und CFO | 1 | Investing.com Deutsch | ||
| 12.11.25 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.25 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.25 | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,510 | -0,68 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| RELAY THERAPEUTICS | 9,350 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BULLFROG AI | 1,070 | 0,00 % | Bullfrog AI stock offers a rare opportunity for investors to take profit | ||
| ALUMIS | 20,130 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,165 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,940 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| NUVALENT | 96,81 | +0,16 % | Wells Fargo stuft Nuvalent wegen hohem Medikamentenpotenzial mit "Overweight" ein | ||
| ARCELLX | 114,76 | +0,17 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| CG ONCOLOGY | 63,90 | -1,19 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ARRIVENT BIOPHARMA | 21,010 | -1,82 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,650 | -5,78 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| APOGEE THERAPEUTICS | 78,69 | 0,00 % | BTIG reiterates Buy on Apogee Therapeutics stock, $137 target | ||
| COGENT BIOSCIENCES | 35,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| TYRA BIOSCIENCES | 34,590 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen |
Das Unternehmen CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.